Eupraxia Pharmaceuticals (EPRX) Enterprise Value (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Enterprise Value data on file, last reported at -$140.5 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 383.98% year-over-year to -$140.5 million in Q1 2026; TTM through Mar 2026 was -$140.5 million, a 383.98% decrease from a year earlier, with the FY2025 full-year figure at -$82.2 million, down 136.99% from the prior year.
• Enterprise Value for Q1 2026 stood at -$140.5 million, down from -$82.2 million in the prior quarter.
• Over the last five years, Enterprise Value for EPRX reached as high as -$8.0 million in Q4 2022 and fell as low as -$140.5 million in Q1 2026.
• Historically, Enterprise Value has averaged -$45.4 million across 5 years, with a median of -$29.0 million in 2025.
• On a YoY basis, Enterprise Value climbed as much as 22.28% in 2025 and fell as far as 787.32% in 2025.
• Year by year, Enterprise Value stood at -$8.0 million in 2022, then tumbled by 157.96% to -$20.7 million in 2023, then slumped by 67.75% to -$34.7 million in 2024, then slumped by 136.99% to -$82.2 million in 2025, then sank by 70.98% to -$140.5 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$140.5 million in Q1 2026, -$82.2 million in Q4 2025, and -$90.5 million in Q3 2025.